HIMS241227C18000
- 12.21
- 0.000.00%
Hims & Hers Health Newsroom
Morgan Stanley Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $42
Strong Buy Recommendation for Hims & Hers Health Amid Growth Potential and Market Volatility
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $18
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
Truist Financial Issues a Hold Rating on Hims & Hers Health (HIMS)
Unusual Options Activity: HIMS, FN and Others Attract Market Bets, HIMS V/OI Ratio Reaches 115.4
EST Dec 20th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Hims & Hers Health: Sell Rating Due to Compounding Exemption Risks and Uncertain GLP-1 Contributions
Sector Update: Health Care Stocks Mixed Premarket Friday
Daily short sale tracking: Micron Technology's short volume increased by 4 million, with a short sale ratio of 11%
Micron Technology(MU.US) ranked top of the list had the largest change in short volume (4.13 million shares), and the short volume ratio of Targa Resources(TRGP.US) reached 45.12%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Hims & Hers Health Shares Fall on FDA Declaration of End to Tirzepatide Shortage
Hims & Hers Health Options Spot-On: On December 19th, 150.18K Contracts Were Traded, With 641.97K Open Interest
On December 19th ET, $Hims & Hers Health(HIMS.US)$ had active options trading, with a total trading volume of 150.18K options for the day, of which put options accounted for 47.42% of the total
Unusual Options Activity: SNAP, WMT and Others Attract Market Bets, SNAP V/OI Ratio Reaches 1136.4
EST Dec 19th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Hims & Hers Health Are Falling Today: What's Going On?
The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com
FDA Clarifies Policies For Compounders As National GLP-1 Supply Begins To Stabilize; Does Not Intend To Take Action Against Compounders For Violations Of FD&C Act Arising From Conditions That Depend On Tirzepatide Injection
The affordable Weight Loss Drugs concept stock Hims & HERS fell 13% in Pre-Market Trading.
On December 19, Glonghui reported that the discount Weight Loss Drugs stock Hims & HERS fell 13% in Pre-Market Trading. Previously, the USA Food and Drug Administration (FDA) stated that the supply shortage of the Eli Lilly and Co Weight Loss Drugs injectable Tirzepatide has been addressed.
FDA Issued A New Decision Determining The Tirzepatide Injection Shortage Is Resolved
10 Health Care Stocks With Whale Alerts In Today's Session
Hims & Hers Health Insider Sold Shares Worth $6,244,284, According to a Recent SEC Filing
Hims & Hers Health Options Trading: A Deep Dive Into Market Sentiment